Brought to you by 
GSK licenses Gilead's HBV drug for developing countries
28 May 2002
Executive Summary
GlaxoSmithKline licensed exclusive development and marketing rights in certain territories, mainly developing countries, to Gilead's (infectious disease therapeutics) Phase III hepatitis B drug adefovir dipivoxil, paying $10mm in cash up front and up to $30mm more for milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK licenses Gilead's HBV drug for developing countries
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice